2 results
Approved WMOCompleted
To test whether treatment with oral imatinib reduce disease burden and consumption of medical resources.
Approved WMOCompleted
To assess the rate of complete response (CR) in Grades III and IV SR-aGVHD participants on Day 28 postrandomization.